| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 113,810 | 79,570 | 26,740 | 100 | 19,550 |
| Sales Growth | +43.03% | +197.57% | +26,639.73% | -99.49% | unch |
| Net Income | -43,960 | -40,860 | -58,330 | -47,250 | -3,450 |
| Net Income Growth | -7.59% | +29.95% | -23.45% | -1,269.57% | unch |
Calliditas Therapeutics Ab ADR (CALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.
Fiscal Year End Date: 12/31